Table 1.
Basic information of the selected medicines.
| Brandname | API | Main indication | Approval date(EMA) | No. of authorized countriesa | No. of reimbursed countriesb |
|---|---|---|---|---|---|
| BavencioTM | Avelumab | MCC | 18 September 2017 | 9 (5) | 5 (41.7%) |
| BlincytoTM | Blinatumomab | ALL | 23 November 2015 | 10 (6) | 8 (66.7%) |
| CometriqTM | Cabozantinib | Medullary thyroid carcinoma | 21 March 2014 | 8 (4) | 6 (50.0%) |
| DeltybaTM | Delamanid | MDR-TB | 23 April 2014 | 6 (2) | 6 (50.0%) |
| HoloclarTM | human corneal cells with stem cells | limbal stem cell deficiency | 17 February 2015 | 4 (0) | 2 (16.7%) |
| LartruvoTM | Olaratumab | soft tissue sarcoma | 9 November 2016 | 8 (4) | 6 (50.0%) |
| NatparTM | Parathyroid hormone | chronic hypoparathyroidism | 24 April 2017 | 5 (1) | 3 (25.0%) |
| NinlaroTM | Ixazomib | multiple myeloma | 21 November 2016 | 10 (6) | 6 (50.0%) |
| OcalivaTM | Obeticholic acid | primary biliary cholangitis | 12 December 2016 | 5 (1) | 5 (41.7%) |
| SirturoTM | Bedaquiline | MDR-TB | 5 March 2014 | 9 (5) | 6 (50.0%) |
| TranslarnaTM | Ataluren | Duchenne muscular dystrophy | 31 July 2014 | 4 (0) | 4 (33.3%) |
| VenclyxtoTM | Venetoclax | CLL | 5 December 2016 | 9 (5) | 5 (41.7%) |
| ZalmoxisTM | Allogeneic T cells | HSCT | 18 Auguest 2016 | 4 (0) | 0 (0.0%) |
MDR-TB, multidrug resistant tuberculosis; ALL, acute lymphoblastic leukemia; HSCT, haploidentical haematopoietic stem cell transplantation; CLL, chronic lymphocytic leukaemia; MCC, metastatic Merkel cell carcinoma. aMaximum number of countries is 12 and 8 between brackets, which excluded EU countries. bNumber of countries where the selected medicines were reimbursed, % out of 12 in brackets.